AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 152 min read$BIVI

BioVie's Bezisterim Shows Phase 2 Signal In Long COVID; Stock Down

BioVie Inc. (BIVI) reported Phase 2 trial results for Bezisterim, showing significant improvements in Long COVID patients with high baseline fatigue and cognitive impairment. The drug demonstrated advantages over placebo on 21 of 22 endpoints and had a similar safety profile to placebo. BioVie plans to advance to Phase 3 trials. BIVI stock is down 8.23% in pre-market trading.

Original reporting
rttnews.com
Published Sep 15, 2026, 3:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 4:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BioVie's Bezisterim Shows Phase 2 Signal In Long COVID; Stock Down — source image
Source · rttnews.com
Decision brief

The 30-second read

$BIVIBullishMed
01

Why it matters

The data positions BioVie as a potential leader in this niche, but execution risk remains high.

02

Market read

First report of meaningful Phase 2 data for a Long COVID therapy; likely to move BIVI and influence related biotech stocks.

03

What to watch

Regulatory pathway and reimbursement landscape for Long COVID treatments remain uncertain.

Relevance 8/10Novelty 8/10Timing: pre-market today

Background

Long COVID lacks approved therapies; biotech firms are racing to develop treatments.

Company-level read

Ticker impact

$BIVIBullishHigh confidence
Context

BioVie reported positive Phase 2 data for Bezisterim in Long COVID patients.

Expected impact

Potential short-term upside as traders price in Phase 3 prospects.

Evidence & confidence

First disclosure of robust Phase 2 data for a rare indication; market typically reacts positively to such milestones.

Market effects

Sector

Positive signal for the biotech sector focused on post‑viral syndromes and CNS‑active oral drugs.

Regional

May lift sentiment for U.S. small‑cap biotech stocks.

Global

Could attract interest from global investors tracking Long COVID therapeutics.

Counterpoint

What could challenge this read

Phase 2 success does not guarantee Phase 3 outcomes; investors may remain cautious.

Key entities

  • company
    BioVie Inc.

    NASDAQ‑listed biotech developing Bezisterim.

  • drug
    Bezisterim

    Oral candidate targeting inflammation and insulin sensitivity.

Read at source← All news

Related articles

SEP 15
$BIVIMedAI 9/10

BioVie, Inc.: BioVie Announces Topline Results from Phase 2 ADDRESS-LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

BioVie Inc. (BIVI) reported positive Phase 2 trial results for bezisterim, showing statistically significant benefits in Long COVID patients with high baseline fatigue, cognitive impairment, and post-exertional malaise. The drug outperformed placebo on 21 of 22 endpoints in these subgroups, with a safety profile similar to placebo. The company plans to discuss the results in a conference call today.

finanznachrichten.de2 min
SEP 8
$BIVIMed

BioVie advances Parkinson’s Phase 3 development program with FDA engagement

BioVie Inc. (BIVI, BIVIW) announced plans to advance its Phase 3 trial for bezisterim in Parkinson’s disease, with an End-of-Phase 2 meeting requested with the FDA. The trial will focus on motor symptoms (MDS-UPDRS Part III) as the primary endpoint, with non-motor symptoms (MDS-UPDRS Part I) as a co-primary or secondary endpoint. Phase 2 results suggested greater benefits for patients with higher inflammation levels. The company expects to discuss the trial design with the FDA later this year an

proactiveinvestors.com2 min
AUG 7
$BIVIMedAI 8/10

BioVie stock sinks on Phase IIb Parkinson’s trial data

BioVie (NASDAQ: BIVI) shares fell after Phase IIb Parkinson’s trial data. On Aug. 6 the stock opened 33.3% lower at $1.36, briefly down nearly 60% to $0.82, then closed at $1.35, down 33.8% from Aug. 5. The data were released alongside a filing for a stock offering at $1.33 per share.

yahoo.com4 min
AUG 6
$BIVIMedAI 8/10

BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim

BioVie Inc (NASDAQ:BIVI) reported positive Phase 2 SUNRISE-PD results for its Parkinson's candidate bezisterim. The drug met prespecified endpoints in early-stage, untreated patients, improving blood inflammatory markers and EPNIC-15 versus placebo. Benefits were strongest in patients with higher baseline platelet counts. Safety was similar to placebo, with 39.3% adverse events vs 51.7%.

proactiveinvestors.com4 min